Javier Angel Navarro-Cossio

Mr. Javier Angel Navarro-Cossio


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GCGonzalo Pérez de la Cruz
Gonzalo Pérez de la Cruz
Veronica Perez-De la CruzVeronica Perez-De la Cruz
Veronica Perez-De la Cruz
JNJavier Angel Navarro-Cossio
Javier Angel Navarro-Cossio
GCGustavo Ignacio Vázquez Cervantes
Gustavo Ignacio Vázquez Cervantes
ASAleli Salazar
Aleli Salazar
BPBENJAMIN PINEDA
BENJAMIN PINEDA
Kynureninase (KYNU) is a kynurenine pathway (KP) enzyme that produces metabolites with immunomodulatory properties. In recent years, overactivation of KP has been associated with poor prognosis of several types of cancer, in particular by promoting the invasion, metastasis, and chemoresistance of cancer cells. However, the role of KYNU in gliomas remains to be explored. In this study, we used the available data from TCGA, CGGA and GTEx projects to analyze KYNU expression in gliomas and healthy tissue, as well as the potential contribution of KYNU in the tumor immune infiltrate. In addition, immune-related genes were screened with KYNU expression. KYNU expression correlated with the increased malignancy of astrocytic tumors. Survival analysis in primary astrocytomas showed that KYNU expression correlated with poor prognosis. Additionally, KYNU expression correlated positively with several genes related to an immunosuppressive microenvironment and with the characteristic immune tumor infiltrate. These findings indicate that KYNU could be a potential therapeutic target for modulating the tumor microenvironment and enhancing an effective antitumor immune response.

2 January 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
DODANIELA RAMIREZ ORTEGA
DANIELA RAMIREZ ORTEGA
EPErick R. Hernández Pérez
Erick R. Hernández Pérez
MMMontserrat Gutiérrez Magdaleno
Montserrat Gutiérrez Magdaleno
KMKarla F. Meza-Sosa
Karla F. Meza-Sosa
LCLucia Pineda Calderas
Lucia Pineda Calderas
Veronica Perez-De la CruzVeronica Perez-De la Cruz
Veronica Perez-De la Cruz
Background: Humulus lupulus (Hops) possesses a diverse array of bioactive compounds with reported antioxidant, anti-inflammatory, antibacterial, and neuroprotective properties. However, most studies have focused on isolated components, whose purification is costly and yields limited quantities. Objective: In this study, we aimed to evaluate whether a complete Hops extract could exert antioxidant and neuroprotective effects. Methods: First, the ability of Hops extract’s free radical scavenging capacity against superoxide, hydroxyl radical, and peroxynitrite was discovered using combinatorial chemical assays. Moreover, the used Hops extract prevented both DNA and protein degradation induced by hydroxyl radicals. Next, rats were orally administered with three different doses of Hops extract (10, 15, and 20 mg/kg/day) for 7 consecutive days. Results: Ex vivo analyses of brain tissues revealed that Hops pre-treatment attenuated FeSO4-induced lipid peroxidation, increased the GSH/GSSG ratio and downregulated both glutathione peroxidase and reductase activities. Additionally, the expression of the nuclear factor erythroid 2-related factor (Nrf2) gene was significantly elevated in the striatum of Hops-treated animals. To further explore neuroprotection, we evaluated the effect of Hops (15 mg/kg/day) in an in vivo model of excitotoxicity induced by quinolinic acid (QUIN). Pre-treatment with the Hops extract reduced QUIN-induced circling behavior, increased the translocation of NRF2 to the nucleus and decreased apoptosis in the striatum. Conclusion: These findings suggest that the whole Hops extract enhances redox resilience in the brain and confers protection against oxidative and excitotoxic insults.

2 November 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
GCGustavo Ignacio Vázquez Cervantes
Gustavo Ignacio Vázquez Cervantes
JNJavier Angel Navarro-Cossio
Javier Angel Navarro-Cossio
GCGonzalo Pérez de la Cruz
Gonzalo Pérez de la Cruz
ASAleli Salazar
Aleli Salazar
Veronica Perez-De la CruzVeronica Perez-De la Cruz
Veronica Perez-De la Cruz
BPBENJAMIN PINEDA
BENJAMIN PINEDA
Indoleamine dioxygenase (IDO), a rate limiting enzyme of the tryptophan catabolism through the kynurenine pathway (KP), has been related with a lower survival and a poor patient prognosis on several solid tumors, including gliomas. However, the use of IDO inhibitors as a therapeutic strategy for tumor treatment remains controversial in clinical trials and the role of other KP enzymes on tumor progression has remained poorly understood so far. Recently, different studies on different types of cancer have pointed out the importance of KP enzymes downstream IDO. Because of this, we conducted a bioinformatic analysis of the expression of different KP enzymes and their correlation with the gene expression of molecules related to the hallmarks of cancer in transcriptomic datasets from patients with different types of brain tumors including low grade gliomas, glioblastoma multiforme, neuroblastoma, and paraganglioma and pheochromocytoma. We found that KP enzymes that drive to NAD+ synthesis are overexpressed on different brain tumors compared to brain cortex data. Moreover, these enzymes presented positive correlations with the expression of genes related to immune response modulation, angiogenesis, Signal Transducer and Activator of Transcription (STAT) signaling, and Rho GTPase expression. These correlations suggest the relevance of the expression of the KP enzymes in brain tumor pathogenesis.